Limited distribution networks stifle competition in the generic and biosimilar drug industries

American Journal of Managed Care

Volumn 24, Issue 4, 2018, Pages e122-e127

  Karas, Laura ^a   Shermock, Kenneth M ^b   Proctor, Celia ^b   Socal, Mariana ^a   Anderson, Gerard F ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; GENERIC DRUG;

COMPETITION; DRUG INDUSTRY; DRUG MARKETING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; PATIENT CARE; PRIORITY JOURNAL; REVIEW; COST; DRUG COST; ECONOMIC ASPECT; ECONOMICS; FOOD AND DRUG ADMINISTRATION; HEALTH CARE DELIVERY; HUMAN; ORGANIZATION AND MANAGEMENT; UNITED STATES;

BIOSIMILAR PHARMACEUTICALS; COSTS AND COST ANALYSIS; DRUG COSTS; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; HEALTH SERVICES ACCESSIBILITY; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85044976064     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. Ellis M. Patient support services: Limited distribution drugs. Presented at: CBI's Specialty Therapies - A Forum for Payers; January 28-29, 2016; Las Vegas, NV. cbinet.com/sites/default/files/files/Ellis-Mike-pres. pdf. Accessed June 10, 2017.
2. Bolger PC. Fine-tuning specialty distribution. Pharmaceutical Commerce website. pharmaceuticalcommerce. com/business-and-finance/fine-tuning-specialty-distribution. Published June 13, 2009. Accessed June 10, 2017.
3. S Rep No. 114-429 (2016). congress.gov/congressional-report/114th-congress/senate-report/429/1.
4. Silverman E. How Martin Shkreli prevents generic versions of his pricey pill. Pharmalot website. pharmalot.com/ how-martin-shkreli-prevents-generic-versions-of-his-pricey-pill. Published October 5, 2015. Accessed June 10, 2017.
5. Hearings Before the US Senate Special Committee on Aging, 114th Cong, 2nd Sess (2016) (testimony of Howard Dorfman).
6. FDA basics webinar: A brief overview of Risk Evaluation and Mitigation Strategies (REMS). FDA website. www. fda.gov/AboutFDA/Transparency/Basics/ucm325201.htm. Updated December 30, 2017. Accessed June 10, 2017.
7. Approved Risk Evaluation and Mitigation Strategies (REMS). FDA website. www.accessdata.fda.gov/scripts/ cder/rems/index.cfm. Accessed March 8, 2018.
8. Federal Food, Drug, and Cosmetic Act, 21 USC §355-1(f)(8) (2007).
9. Center for Drug Evaluation and Research. Guidance for industry: Bioavailability and bioequivalence studies for orally administered drug product - general considerations. FDA website. www.fda.gov/ohrms/dockets/ ac/03/briefing/3995B1-07-GFI-BioAvail-BioEquiv.pdf. Published July 10, 2002. Accessed June 10, 2017.
10. Biosimilars. FDA website. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/Biosimilars. Updated November 14, 2017. Accessed June 10, 2017.
11. Examining the Impact of Voluntary Restricted Distribution Systems in the Pharmaceutical Supply Chain: Hearings Before the Subcommittee on Health Care, Benefits, and Administrative Rules of the House Committee on Oversight and Government Reform, 115th Cong, 1st Sess (2017) (testimony of Bruce Leicher).
12. Examining the Impact of Voluntary Restricted Distribution Systems in the Pharmaceutical Supply Chain: Hearings Before the Subcommittee on Health Care, Benefits, and Administrative Rules of the House Committee on Oversight and Government Reform, 115th Cong, 1st Sess (2017) (testimony of Janet Woodcock, MD).
13. Sarpatwari A, Avorn J, Kesselheim AS. Using a drug-safety tool to prevent competition. N Engl J Med. 2014;370(16):1476-1478. doi: 10.1056/NEJMp1400488.
14. Federal Food, Drug, and Cosmetic Act, 21 USC §355-1(i)(1)(B) (2007).
15. Grande A. Celgene, Barr resolve spat over generic Thalomid. Law360 website. law360.com/articles/171392/ celgene-barr-resolve-spat-over-generic-thalomid. Published May 26, 2010. Accessed June 10, 2017.
16. James B. Barr strikes back at Celgene in Thalomid spat. Law360 website. law360.com/articles/37260/barrstrikes-back-at-celgene-in-thalomid-spat. Published October 11, 2007. Accessed June 10, 2017.
17. Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA website. www.accessdata.fda.gov/scripts/cder/ob. Updated January 2018. Accessed March 23, 2018.
18. Lexi-Drugs. Wolters Kluwer website. webstore.lexi.com/Lexi-Drugs. Accessed March 23, 2018.
19. Drugs@FDA: FDA approved drug products. FDA website. www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed March 23, 2018.
20. Pollack A. Drug goes from $13.50 a tablet to $750, overnight. The New York Times. September 20, 2015. nytimes.com/ 2015/09/21/business/a-huge-overnight-increase-in-a-drugs-price-raises-protests.html. Accessed June 10, 2017.
21. Wattles J. Drugmaker fined $100M for hiking price 85, 000%. CNN Money website. money.cnn.com/2017/01/ 18/news/drug-pricing-mallinckrodt-ftc-fine/index.html. Published January 18, 2017. Accessed June 10, 2017.
22. Stobbe M. Premature labor drug spikes from $10 to $1500. NBCNews.com website. nbcnews.com/id/4199 4697/ns/health-pregnancy/t/premature-labor-drug-spikes. Published March 9, 2011. Accessed June 10, 2017.
23. Staton T. The huge price hike as sales strategy, taken to extremes by Retrophin. FiercePharma website. fiercepharma.com/financials/huge-price-hike-as-sales-strategy-taken-to-extremes-by-retrophin. Published September 11, 2014. Accessed June 10, 2017.
24. FAST Generics Act of 2017, HR 2051, 115th Cong, 1st Sess, §2 (2017).
25. FAST Generics Act of 2017, HR 2051, 115th Cong, 1st Sess, §3 (2017).
26. CREATES Act of 2017, S 974, 115th Cong, 1st Sess, §3 (2017).
27. Manufacturer notices to covered entities. Health Resources and Services Administration website. hrsa.gov/ opa/manufacturer-notices/index.html. Updated February 2018. Accessed March 8, 2018.
28. CREATES Act of 2017, S 974, 115th Cong, 1st Sess, §2 (2017).
29. Brill A. Lost prescription drug savings from use of REMS programs to delay generic market entry. Association for Accessible Medicines website. gphaonline.org/media/cms/REMS-Studyfinal-July2014.pdf. Published July 2014. Accessed June 10, 2017.
30. Welch, McKinley introduce bipartisan bill to increase consumer access, drive down costs, and boost market competition for generic pharmaceuticals [news release]. Washington, DC; US Congressman Peter Welch representing Vermont; April 7, 2017. welch.house.gov/media-center/press-releases/welch-mckinleyintroduce-bipartisan-bill-increase-consumer-access-drive. Accessed September 6, 2017.
31. Leaders of Senate and House Judiciary Committees reintroduce bipartisan legislation to counter rising prescription drug prices [news release]. Washington, DC; US Senator Patrick Leahy of Vermont; April 27, 2017. leahy.senate.gov/press/leaders-of-senate-and-house-judiciary-committees-reintroduce-bipartisanlegislation-to-counter-rising-prescription-drug-prices. Accessed September 6, 2017.
32. World Preview 2016, Outlook to 2022. 9th ed. London, UK: EvaluatePharma; 2016. info.evaluategroup.com/ rs/607-YGS-364/images/wp16.pdf.